|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| https://www.sciencedirect.com/science/article/pii/S0889159121000866#m0006 | **One months follow-up cohort (n=402)** | **Drop-out (n=176)** | **Three months follow-up cohort (n=226)** | **Drop-out vs three months** | | | **One month vs three months** | | |
| **t or χ2** | **P** | **FDR-adjusted p-value** | **t or χ2** | **p** | **FDR-adjusted p-values** |
| **Sex -** males (females) | 265 (137) | 117 (59) | 149 (77) | 0.01 | 0.908 | 0.961 | 0.01 | 0.998 | 0.999 |
| **Psychiatric history -** negative (positive) | 296 (106) | 132 (44) | 164 (62) | 0.31 | 0.582 | 0.852 | 0.083 | 0.772 | 0.999 |
| **Setting -** outpatient (inpatient) | 102 (300) | 53 (123) | 49 (177) | 0.76 | 0.38 | 0.725 | 0.287 | 0.591 | 0.999 |
| **Age** | 57.80±13.33 | 56.8±14.09 | 58.5±12.83 | -1.26 | 0.208 | 0.504 | -0.76 | 0.449 | 0.999 |
| **Duration of hospitalization** | 16.64±12.89 | 15.6±11.63 | 15.32±9.45 | 0.22 | 0.824 | 0.961 | 0.87 | 0.384 | 0.999 |
| **ZSDS index at one month** | 44.24±11.40 | 42.88±9.87 | 45.15±12.33 | -1.91 | 0.057 | 0.342 | -0.87 | 0.385 | 0.999 |
| **BDI-13 at one month** | 3.28±4.40 | 2.94±3.62 | 3.56±4.93 | -1.36 | 0.174 | 0.504 | -0.94 | 0.345 | 0.999 |
| **IES-R at one month** | 23.83±20.02 | 21.61±18.72 | 25.97±20.95 | -2.08 | 0.038 | 0.342 | -1.30 | 0.194 | 0.999 |
| **PCL-5 at one month** | 14.49±15.85 | 13.27±14.52 | 15.64±16.85 | -1.37 | 0.17 | 0.504 | -0.81 | 0.417 | 0.999 |
| **STAI-Y trait at one month** | 35.99±10.70 | 37.7±10.27 | 38.62±11.68 | -0.77 | 0.444 | 0.726 | -0.70 | 0.485 | 0.999 |
| **STAI-Y state at one month** | 38.19±11.09 | 35.17±10.4 | 36.57±10.89 | -1.22 | 0.224 | 0.504 | -0.61 | 0.541 | 0.999 |
| **OCI at one month** | 11.82±10.17 | 11.06±10.02 | 12.46±10.25 | -1.3 | 0.196 | 0.504 | -0.01 | 0.988 | 0.999 |
| **WHIIRS at one month** | 7.25±5.03 | 7.33±5.13 | 7.24±5.02 | 0.17 | 0.867 | 0.961 | -0.22 | 0.826 | 0.999 |
| **Baseline NLR** | 5.55±3.09 | 5.4±4.9 | 5.69±5.35 | -0.5 |  | 0.852 | -0.32 | 0.750 | 0.999 |
| **Baseline MLR** | 0.52±0.28 | 0.51±0.34 | 0.51±0.4 | -0.01 | 0.99 | 0.990 | -0.35 | 0.728 | 0.999 |
| **Baseline SII** | 1280.03±1023.89 | 887.35±669.39 | 802.39±844.19 | 0.84 | 0.403 | 0.725 | -1.09 | 0.275 | 0.999 |
| **Baseline CRP (mg/ml)** | 67.35±40.80 | 58.25±55.64 | 74.27±77.55 | -2.15 | 0.032 | 0.342 | 0.08 | 0.936 | 0.999 |
| **Follow-up oxygen saturation level** | 97.85±1.34 | 97.93±1.2 | 97.91±1.4 | 0.16 | 0.873 | 0.961 | -0.76 | 0.449 | 0.999 |

Differences between three-month follow-up cohort and drop-out group and between initial cohort and three months cohort in terms of sociodemographic characteristic, clinical severity, and psychopathology scores at one month (Student’s t test and Chi-square). False Discovery Rate (FDR); Zung Self-rating Depression Scale (ZSDS); Beck's Depression Inventory (BDI); Impact of Event Scale – Revised (IES-R); PTSD Checklist for DSM-5 (PCL-5); State Anxiety Inventory (STAI); Obsessive-Compulsive Inventory (OCI); Women's Health Initiative Insomnia Rating Scale (WHIIRS); neutrophil/lymphocyte ratio (NLR); monocyte/lymphocyte ratio (MLR); systemic immune-inflammatory index (SII).

|  |  |  |
| --- | --- | --- |
|  | **SSRI ± BDZ** | **BDZ** |
| **Depressive episode** (n=20) | 16 | 0 |
| **Anxiety disorder** (n=20) | 10 | 1 |
| **Insomnia** (n=7) | 1 | 5 |
| **Other** (n=8) | 1 | 0 |
| **Total** (n=55) | 28 | 6 |

Diagnosis and psychopharmacological treatment at three months follow-up. Serotonin reuptake inhibitor (SSRI); benzodiazepines (BDZ)

|  |  |  |
| --- | --- | --- |
|  | **Absence of current DSM-5 diagnosis** (n=171) | **Current DSM-5 diagnosis** (n=55) |
| **Negative psychiatric history** (n=164) | 137 | 27 |
| **Positive psychiatric history** (n=62) | 34 | 28 |

Current DSM-5 diagnosis and psychiatric history.